Solutions for the Next Generation of Novel Therapies

  • Our Experienced Team
  • Experienced
    Team of Experts

  • AMPEL BioSolutions combines clinical and biomedical research expertise to bring solutions to research, translational and pragmatic needs.

  • Research
  • Basic & Clinical
    Research

  • The AMPEL team has the tools and insight to anticipate and problem solve clinical research, discovery and development challenges creatively and effectively.

  • Approaches
  • Drug
    Repurposing

  • AMPEL uses innovative thinking to match the right drug with the right patient at the right time.

  • Lupus Research
  • Individualized Medicine
    for Patients

  • AMPEL's LRxL STATTM Drug Repositioning Initiative is accelerating clinical trials on promising and patient-centric treatment options for those suffering from Lupus.

Who We Are

AMPEL BioSolutions is the leading biomedical research think tank that creatively addresses clinical development bottlenecks and R&D roadblocks. AMPEL interrogates, analyzes, synthesizes & interprets the world's biomedical knowledge to provide novel solutions for clinical research questions.

  • Resourceful and dedicated, AMPEL is composed of leading experts in autoimmunity, immunogenicity, inflammation and clinical immunology with extensive research and medical experience to address and resolve obstacles.
  • AMPEL assists nonprofit organizations, pharmaceutical companies, clinical research groups, and others in basic research, translational medicine, preclinical research, drug development and repositioning, and biomarker identification.
AMPEL BioSolutions Team

What's New

Dec
202016

Virginia Bio Welcomes New Members to its Board of Directors

Press Releases

Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected five new members to their Board of Directors for a term of three years. The election took place on December 8,...

Nov
152016

Data mining could lead to therapy advances

Press Releases

In the past 50 years, only one new therapy has been approved for the treatment of lupus. Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA, works to change that, and he will discuss his efforts...

Nov
152016

Meta-Analysis of Gene Expression Data Sets to Identify Novel Molecular Pathways & Drug Targets in Systemic Lupus Erythematosus

Events

On Tuesday, November 15, during the 2016 ACR/ARHP Annual Meeting, Dr Peter Lipsky will give a talk entitled "Meta-Analysis of Gene Expression Data Sets to Identify Novel Molecular Pathways Drug Targets in Systemic Lupus Erythematosus" during the "Mining...

Oct
282016

AMPEL Particpates in UVA Fall Job and Internship Fair

News

On October 26 and 27, 2016 AMPEL participated in the Fall Job and Internship Fair hosted by the University of Virginia. To read more about this event visit: https://www.news.virginia.edu/content/potential-employers-descend-grounds-during-annual-career-fair (https://www.news.virginia.edu/content/potential-employers-descend-grounds-during-annual-career-fair) Grammer, far right, with her team from AMPEL BioSolutions, including from...

Oct
282016

Senator Creigh Deeds stopped by AMPEL BioSolutions

News

Today, Senator Creigh Deeds stopped by AMPEL BioSolutions to visit with our employees and learn about how we are using Big Data to find and test new drugs for lupus patients.  He got to see first-hand how our research is...

Sep
272016

Lupus Research Alliance Announces Published Data Showing Effective Approach to Drug Repositioning

Press Releases

Crowd-sourcing, Literature Review and Big Data Analysis Identify Promising Lupus TreatmentsNEW YORK, NY –- New results published (http://www.ncbi.nlm.nih.gov/pubmed/27497259%29) in the professional journal Lupus demonstrate the effectiveness of an innovative system developed to identify promising treatments for lupus among existing drugs...

Sep
272016

New Results Published Demonstrate Effectiveness of AMPEL's Innovative System

Press Releases

New results published in the professional journal Lupus demonstrate the effectiveness of an innovative system developed to identify promising treatments for lupus among existing drugs approved for use in other diseases. Funded by the Lupus Research Alliance and the John...

Aug
082016

Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis

News

ABSTRACT Drug Repositioning in SLE: crowd-sourcing, literature-mining, and Big Data analysis AC Grammer, MM Ryals, SE Heuer, RD Robl, S Madamanchi, LS Davis, B Lauwerys, MD Catalina, and PE Lipsky Lupus patients are in need of modern drugs to treat specific manifestations of...

Aug
022016

An Interview with Dr Peter Lipsky

News

Below is an interview with Dr. Peter Lipsky which was recorded as part of The Journal of Immunology (The JI) centennial history project. Dr. Lipsky was the Editor-in-Chief of The JI from 1992–1997. He was the recipient of the AAI...

Jun
222016

Pilot study with UVa to explore more ways to tackle lupus

Press Releases

"A pilot study at UVa Research Park will explore the science behind the old saying “mind over matter.” A local company called AMPEL Biosolutions is teaming up with the University of Virginia to examine the effects of contemplative practices — such as...

Jun
222016

FOCIS 2016, Boston

Events

This week, during FOCIS 2016, Amrie Grammer, PhD will give a presentation on the identification of novel drug targets for repositioning in Lupus, in addition to Ampel having two posters at the conference. For more information on FOCIS 2016 visit...

May
142016

IMMUNOLOGY 2016

Events

The American Association of Immunologist is hosting their annual meeting in Seattle this week, May 13-17, 2016, and AMPEL BioSolutions is there! This year AMPEL is presenting their poster entitled Meta-Analysis from Gene Expression Profiles of Lupus Affected Tissues Reveals...

Apr
192016

Ozgur Ekmekci Excellence in Chemistry Award Winners

News

Congratulations to all of the Ozgur Ekmekci Excellence in Chemistry Award winners (sponsored by the UVA Chapter of AXE AMPEL BioSolutions): 1st: Juliana Laszakovits (https://www.facebook.com/july.laszakovits), Univ of Mary Washington 2nd: Youlim Ha (https://www.linkedin.com/in/youlimha?authType=NAME_SEARCH authToken=i37p locale=en_US srchid=2930098121460991295625 srchindex=1 srchtotal=1 trk=vsrp_people_res_name trkInfo=VSRPsearchId%3A2930098121460991295625%2CVSRPtargetId%3A398933992%2CVSRPcmpt%3Aprimary%2CVSRPnm%3Atrue%2CauthType%3ANAME_SEARCH), AK-AXE...

Apr
152016

Alumni Advisory Board of AK-AXE and AMPEL BioSolutions Present Awards in Honor of Ozgur Ekmekci

Events

The Alumni Advisory Board of the Alpha Kappa Chapter of Alpha Chi Sigma is please to announce that anonymous donors and AMPEL BioSolutions have funded awards to honor the memory of Berk Ekmekci's father, Ozgur (https://gwtoday.gwu.edu/memoriam-ozgur-ekmekci;http://patch.com/virginia/ashburn/ozgur-ekmekci-51-0). Berk is a member...

Jun
242015

Dr. George C. Tsokos Receives Lupus Insight Prize at FOCIS 2015 from Dr. Peter Lipsky

Press Releases

George C. Tsokos, M.D., Chief of the Rheumatology Division at Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School, received the 2015 Lupus Insight Prize today for a project with great promise in improving treatment for lupus...

Apr
222015

LRxL-STAT's Top Scoring Biologic Ustekinumab: ALR is Working on A Clinical Trial with Janssen

Press Releases

The Alliance for Lupus Research (ALR) is pleased to announce it is working with Janssen Research Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson Johnson, on a clinical study to evaluate ustekinumab (Stelara®)...

Jan
152015

To Save Lives, Save Virginia Jobs

Press Releases

A new trade deal could have a big impact on Virginia’s economy. Imagine a future free of allergic reactions, lupus and cancer. Virginia scientists are already working to make this a reality: Two Virginia Bioinformatics Institute researchers have created software that...

Jan
092015

Kadmon Corporation’s Lupus Treatment Candidate Designated Top Priority

Press Releases

The Kadmon Corporation’s Phase 2 oral drug, KD025, a potent, bio-available and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2) that can be taken orally was designed as one of its priority candidates to treat lupus through the LRxL-STAT...

Nov
262014

Ampel BioSolutions Identifies Novel Lupus Treatments And Targets

Press Releases

Virginia researchers and founders of AMPEL BioSolutions, Drs. Amrie Grammer and Peter Lipsky delivered the results of a year-long Lupus Drug Repositioning Initiative this week in Boston. The Alliance for Lupus Research (ALR), the Lupus Research Institute (LRI) and AMPEL...

Nov
202014

Treatments for Lupus Patients Repositioned from Other Indications: Top Priority Candidates Announced by the ALR and LRI

Press Releases

Boston, MA -- The Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) launched the Lupus Clinical Investigators Network (LuCIN) that will conduct clinical trials as part of the drug repositioning program LRxL-STAT at the American College of...

Oct
022014

New ALR-LRI Collaboration to Accelerate New Treatments for Lupus

Press Releases

Today, the Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) announced a trailblazing cooperative project to speed up the identification and availability of new treatments for lupus. Details of this new effort focused on identifying new treatments...

Jul
232014

AMPEL BioSolutions' Co-Founder Identifies Novel Lupus Target

Press Releases

July 23 is a big day for Lupus patients – a new target for treatment has been identified. International attention was placed on the disease today in two articles. “Drugs for Treating Systemic Lupus Erythematosus: Global Markets” emphasized the growing...

Feb
262014

ALR-LRI Collaboration to Accelerate New Lupus Treatments Moving at Fast Pace

Press Releases

The Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) are excited to report rapid progress on the cooperative project we launched just months ago to fast-track scientific analysis and identification of potential new treatments for lupus. The...

«
»

Clients & Collaborators

  • Alliance for Lupus Research
  • Lupus Research Institute
  • Janssen Pharmaceuticals, Inc.
  • Kadmon
  • Pfizer
  • GlaxoSmithKline
  • 1
  • 2

About AMPEL

AMPEL BioSolutions is a biomedical research consultation firm specializing in translational and personalized medicine including drug and target identification, protocol design and management, biomarker identification, and bioinformatic analysis.


Read more...

Press Releases

Dec
202016

Virginia Bio Welcomes New Members to its Board of Directors

Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected five new members to their Board of Directors for a term...

Nov
152016

Data mining could lead to therapy advances

In the past 50 years, only one new therapy has been approved for the treatment of lupus. Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA,...

Sep
272016

Lupus Research Alliance Announces Published Data Showing Effective Approach to Drug Repositioning

Crowd-sourcing, Literature Review and Big Data Analysis Identify Promising Lupus TreatmentsNEW YORK, NY –- New results published (http://www.ncbi.nlm.nih.gov/pubmed/27497259%29) in the professional journal Lupus demonstrate the effectiveness of an innovative system...

Sep
272016

New Results Published Demonstrate Effectiveness of AMPEL's Innovative System

New results published in the professional journal Lupus demonstrate the effectiveness of an innovative system developed to identify promising treatments for lupus among existing drugs approved for use in other...

Jun
222016

Pilot study with UVa to explore more ways to tackle lupus

"A pilot study at UVa Research Park will explore the science behind the old saying “mind over matter.” A local company called AMPEL Biosolutions is teaming up with the University of Virginia...

Jun
242015

Dr. George C. Tsokos Receives Lupus Insight Prize at FOCIS 2015 from Dr. Peter Lipsky

George C. Tsokos, M.D., Chief of the Rheumatology Division at Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School, received the 2015 Lupus Insight Prize today for...

Apr
222015

LRxL-STAT's Top Scoring Biologic Ustekinumab: ALR is Working on A Clinical Trial with Janssen

The Alliance for Lupus Research (ALR) is pleased to announce it is working with Janssen Research Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson ...

Jan
152015

To Save Lives, Save Virginia Jobs

A new trade deal could have a big impact on Virginia’s economy. Imagine a future free of allergic reactions, lupus and cancer. Virginia scientists are already working to make this a...

Jan
092015

Kadmon Corporation’s Lupus Treatment Candidate Designated Top Priority

The Kadmon Corporation’s Phase 2 oral drug, KD025, a potent, bio-available and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2) that can be taken orally was designed as one...

Nov
262014

Ampel BioSolutions Identifies Novel Lupus Treatments And Targets

Virginia researchers and founders of AMPEL BioSolutions, Drs. Amrie Grammer and Peter Lipsky delivered the results of a year-long Lupus Drug Repositioning Initiative this week in Boston. The Alliance for...

Contact AMPEL

250 West Main Street, Suite 300

Charlottesville, Virginia 22902

434-296-2675 (AMPL)
Fax: 434-964-9586

info@ampel.org

 

Get Map